RxDoctor Payments Data

Kathleen Moss Grizzard, MD

Internal Medicine · Tampa, FLNPI 1770593923

Payments from drug & device makers

$12,740in general payments, 2019–2025

Across 712 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • AbbVie$2K
  • GSK$1K
  • Amgen$840
  • Pfizer$776
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$12,65099%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,740 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$213,717
Medicare patients
456
Services billed
4,206

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$174,501
EliquisApixaban74$83,530
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$33,010
XareltoRivaroxaban23$20,494
Repatha SureclickEvolocumab17$18,586
LivaloPitavastatin Calcium21$17,663
FarxigaDapagliflozin Propanediol16$9,273
Spiriva RespimatTiotropium Bromide11$9,110
Atorvastatin Calcium377$4,517
Levothyroxine Sodium322$4,412
Rosuvastatin Calcium277$4,163
SynthroidLevothyroxine Sodium74$3,770
Omeprazole186$3,230
Estradiol58$2,751
Desvenlafaxine Succinate ErDesvenlafaxine Succinate23$2,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,705$174,501138 claims
PfizerEliquis$776$83,53074 claims
GSKTrelegy Ellipta$1,383$33,01035 claims
Johnson & JohnsonXarelto$360$20,49423 claims
Kowa Pharmaceuticals America, Inc.Livalo$247$17,66321 claims
AstraZenecaFarxiga$1,757$9,27316 claims
Boehringer IngelheimSpiriva Respimat$163$9,11011 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$4,412322 claims
AbbVieSynthroid$1,583$3,77074 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →